Market Place
Sourcing Support
Ajax to Present Phase 1 Data for AJ1?11095 in Myelofibrosis at ASH
02 Dec 2024 //
BUSINESSWIRE
Ajax Therapeutic Doses 1st Patient in Phase 1 JAK2 Inhibitor Trial
30 Oct 2024 //
BUSINESSWIRE
Ajax Raises $95M Series C For First-In-Class JAK2 Inhibitor
13 May 2024 //
BUSINESSWIRE
Ajax Therapeutics Gets FDA IND Clearance For JAK2 Inhibitor In Myelofibrosis
13 May 2024 //
BUSINESSWIRE
Attack JAK`: Ajax secures $95M to test new JAK2 inhibitor
13 May 2024 //
ENDPTS
Ajax Therapeutics Appoints Dr. David Steensma as Chief Medical Officer
23 Aug 2023 //
BUSINESSWIRE
Ajax Therapeutics Appoints Eric S. Fischer, PhD, to Scientific Advisory Board
24 May 2023 //
BUSINESSWIRE
Ajax Therapeutics Appoints Alan Collis, PhD, as Senior Vice President
09 Mar 2023 //
BUSINESSWIRE
Ajax Presents Preclinical Data on AJ1-10502 at American Society of Hematology
11 Dec 2022 //
BUSINESSWIRE
Ajax Therapeutics Appoints Srdan “Serge” Verstovsek to Scientific Advisory Board
06 Dec 2022 //
BUSINESSWIRE
Ajax Therapeutics Announces Presentations on Next?Generation JAK2 Inhibitors
03 Nov 2022 //
BUSINESSWIRE
DisperSol, Ajax Collaborate to Develop Enhanced KinetiSol Drug Formulations
17 Dec 2021 //
BUSINESSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.